5433-39-6

Usage

Uses

Used in Pharmaceutical Industry:
N-(3-pyridinylcarbonyl)benzenesulfonohydrazide is used as a reagent for the synthesis of various pharmaceuticals due to its unique chemical structure and properties.
Used in Agrochemical Industry:
N-(3-pyridinylcarbonyl)benzenesulfonohydrazide is also used as a reagent in the synthesis of agrochemicals, contributing to the development of new products for agricultural applications.
Used in Drug Development:
N-(3-pyridinylcarbonyl)benzenesulfonohydrazide is used as a candidate for drug development because of its potential anti-inflammatory and analgesic properties, which could be harnessed to create new medications for pain relief and inflammation management.
Used in Oncology Research:
In the field of oncology, N-(3-pyridinylcarbonyl)benzenesulfonohydrazide is used as a subject of research for its promising anticancer activity, with potential applications in developing new cancer treatments.

Upstream product

• 553-53-7 Nicotinic acid hydrazide 
• 98-09-9 benzenesulfonyl chloride 
• 93-60-7 methyl 3-pyridinecarboxylate 

Downstream Products

• 882-33-7 diphenyldisulfane 
• 66310-17-6 3-benzoyloxymethyl-1-methyl-pyridinium; iodide 
• 13441-54-8 3-formylpyridinium methiodide 
• 58550-50-8 pyridin-3-ylmethyl benzoate 
• 17470-24-5 2-amino-3-(pyridin-3-yl)propanoic acid 
• 100-55-0 3-hydroxymethylpyridin 
• 500-22-1 3-pyridinecarboxaldehyde 
• 109966-43-0 pyridine-3-carbaldehyde-(4-o-tolyl thiosemicarbazone) 
• 110029-19-1 pyridine-3-carbaldehyde-(4-p-tolyl thiosemicarbazone) 
• 107681-96-9 pyridine-3-carbaldehyde-[4-(2-methoxy-phenyl)-thiosemicarbazone] 
• 107682-76-8 pyridine-3-carbaldehyde-[4-(4-methoxy-phenyl)-thiosemicarbazone] 

Relevant academic research and scientific papers

Synthesis of N'-nicotinoyl sulfonohydrazides and their antimicrobial activity

N'-Nicotinoyl sulfonohydrazide derivatives 3-13 were synthesized from nicotinyl hydrazide and evaluated for their antimicrobial potential against Gram positive bacterial strains (Bacillus cereus, Bacillus subtilis, Corynebacterium diphtheriae, Staphylococcus fecalis, Staphylococcus aureus, and MRSA (Methicillin-resistant Staphylococcus aureus)) and Gram negative bacterial strains (Escherichia.coli, Pseudomonas aeruginosa, Salmonella ParatyphiB, Salmonella tyhpi). Compound 13 showed outstanding antibacterial activity against Staphylococcus fecalis and compounds 7 and 13 were found to be moderately activite against Salmonella Paratyphi B, shown by their zone of inhibition values. In addition to that compond 9 also showed moderate activity against Escherichia coli. All derivatives 3-13 were also subjected for the evaluation of their antifungal activity against Saccharomyces cerevisiae, Microsporum canin, Rhizopus, Aspergillus niger, Candida albicans, and Candida tropicalis. Compound 13 showed promising antifungal activity against Rhizopus sp. and compounds 9 and 10 showed moderate antifungal potential against Microsporum canis, Aspergillus niger, and Candida tropicalis. Other molecules demonstrated weak zone of inhibitions.

Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof

Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular and neurovascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, inflammatory disorders, immunological disorders, oxidative stress, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, wherein, R1, R2, R3, X and m are as defined in the specification. Also disclosed is a method for preparation of the compounds of general formula (I) and pharmaceutical composition containing one or more compounds as defined above as active ingredients. Also disclosed is a method of treatment of a diabetic patient by administering the compounds as defined above, either singly or in combination with drugs for antidiabetic therapy.